Tamarack Advisers’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Tamarack Advisers’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-595,000	Closed	-$14.3M	–	41
2019 Q4	$14.3M	Sell	595,000 -405,000	-41%	-$11.2M	3.26%	13
2019 Q3	$26.8M	Buy	1,000,000 +445,000	+80%	+$12.5M	6.99%	5
2019 Q2	$14.4M	Sell	555,000 -170,000	-23%	-$5.33M	4.38%	9
2019 Q1	$25.2M	Buy	725,000 +325,000	+81%	+$9.38M	9.99%	4
2018 Q4	$7.81M	Buy	+400,000	New	+$8.23M	3.18%	13

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Tamarack Advisers's PTLA Position: Q1 2020 in Review

Tamarack Advisers sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 595,000 shares — an estimated $14.3M sold.

Tamarack Advisers first reported a position in PTLA in Q4 2018 and held it in 5 quarters. The position peaked at $26.8M in Q3 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Tamarack Advisers reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Tamarack Advisers sold 595,000 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $14.3M.
Tamarack Advisers first reported a position in Portola Pharmaceuticals, Inc. in Q4 2018 and held it in 5 quarters.
Tamarack Advisers's Portola Pharmaceuticals, Inc. position peaked at $26.8M in Q3 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Tamarack Advisers's 13F filing for Q1 2020, filed 14 May 2020.